The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Abstract
PURPOSE: The penetration of intravitreally injected bevacizumab in its commercial formulation (Avastin; Roche, Grenzach, Germany) through the retina was studied, to determine whether a full-length antibody would be able to penetrate the retina as easily as an antibody fragment. METHODS: Six cynomolgus monkeys (Macaca fascicularis) were used in this study. Two compositions of intravitreal injection into the right eyes were performed: one with commercial Avastin (group 1, four animals) and the other one with commercial Avastin labeled with 125I (group 2, one animal). The animals in group 1 were killed 1, 4, 7, or 14 days after the injection for subsequent histologic analysis of the eyes by immunohistochemistry, and the animal in group 2 was killed 7 days after injection for autoradiography and electron microscopy. Funduscopy was performed before the injection and at several time points thereafter. Moreover, blood samples were collected at different time points from the group-2 animal. The sixth animal remained untreated and served as the control. RESULTS: No pathologic changes were obvious in the funduscopic images within the time of the experiment. Bevacizumab immunoreactivity was found in the choroid and the inner layers of the retina as early as 1 day after the injection and spread to the outer layers and the choroid within the following days, in particular to photoreceptors and blood vessels. Avastin labeled with 125I showed radioactivity in blood serum 1 day after the intravitreal injection and remained relatively stable until day 7. CONCLUSIONS: The results clearly show that the bevacizumab molecule can penetrate the retina and is also transported into the retinal pigment epithelium, the choroid and, in particular, into photoreceptor outer segments after intravitreal injection of Avastin. Active transport mechanisms seem to be involved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
GREENWOOD, F., HUNTER, W., & GLOVER, J. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,152
Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity
HUNTER, W. M., & GREENWOOD, F. C. (1962) · Nature · doi:10.1038/194495a0 · Cited by 6,919
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Vascular endothelial growth factors and angiogenesis in eye disease
Witmer, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00043-5 · Cited by 927
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Cited by
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269
Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature
Stanescu-Segall, D., Balta, F., & Jackson, T. L. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.04.004 · Cited by 175
Neutralisation of adeno-associated virus transduction by human vitreous humour
Andrzejewski, S., Moyle, P. M., Stringer, B. W., Steel, J. C., & Layton, C. J. (2021) · Gene Therapy · doi:10.1038/s41434-020-0162-8 · Cited by 10
Metadata
- Authors
- Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., & Schraermeyer, U.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2007-06-01
- Volume
- 48
- Issue
- 6
- Pages
- 2814
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2039936409
- Cited by
- 253
- References
- 27
- FWCI
- 24.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey. https://app.cochat.ai/papers/10.1167/iovs.06-1171
- The paper
- Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., & Schraermeyer, U. (2007). Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.06-1171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.